Spots Global Cancer Trial Database for anemia
Every month we try and update this database with for anemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effects of Preoperative Correction of Anemia With Intravenously Iron in Colorectal Cancer Patients. | NCT05221957 | Colorectal Canc... Anemia Iron-deficiency | Iron(III)isomal... | 18 Years - | Zealand University Hospital | |
| A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer | NCT00246597 | Anemia Breast Neoplasm... Hemoglobins Quality of Life Chemotherapy, A... | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| Clinical Tumor Anemia Registry (TAR) | NCT01795690 | Anemia | 18 Years - | iOMEDICO AG | ||
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | NCT02243124 | Myelodysplastic... | cenersen Dexamethasone | 18 Years - 95 Years | Eleos, Inc. | |
| A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies | NCT00776425 | Anemia | Epoetin beta | 18 Years - | Hoffmann-La Roche | |
| Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients | NCT00628043 | Anemia | epoetin beta placebo | 20 Years - 79 Years | Chugai Pharmaceutical | |
| A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. | NCT00350090 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| Retrospective Study on the Incidence and Management of Anemia in Oncology | NCT04779840 | Anemia Cancer | anemia assessme... | 18 Years - | Weprom | |
| A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B | NCT02608060 | Anemia | Epoetin Beta | 18 Years - | Hoffmann-La Roche | |
| A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study | NCT00115167 | Anemia Cancer | Placebo Darbepoetin alf... | 18 Years - | Amgen | |
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | NCT00381836 | Prostatic Neopl... Anemia | Darbepoetin Alf... | 18 Years - | University of Aarhus | |
| A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia | NCT00117039 | Anemia Neoplasms | Aranesp® | 18 Years - | Amgen | |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | NCT00843882 | Anemia Chronic Myelomo... de Novo Myelody... Myelodysplastic... | Bone Marrow Bio... Epoetin Alfa Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | NCT00004917 | Anemia Head and Neck C... | epoetin alfa cisplatin radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies | NCT00239239 | Non-Myeloid Mal... Anemia Cancer | Darbepoetin alf... | 18 Years - | Amgen | |
| Chemotherapy Related Anemia | NCT00035607 | Anemia Non-Myeloid Mal... | Darbepoetin alf... Darbepoetin alf... | 18 Years - | Amgen | |
| A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) | NCT05568225 | Very Low Risk, ... | Etavopivat | 18 Years - | Novo Nordisk A/S | |
| Perioperative Management of Preoperative Anemia in Colorectal Cancer | NCT06026618 | Anemia Colorectal Canc... | 18 Years - | Consorci Sanitari Integral | ||
| Anemia and Red Blood Cells Transfusion in Oncological Surgery | NCT04101240 | Anemia Surgery Oncology | 18 Years - | University Hospital, Brest | ||
| An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes | NCT01381809 | Myelodysplastic... | Group 2: Placeb... Group 1: Epoeti... | 18 Years - | Janssen-Cilag International NV | |
| Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | NCT05913414 | Nasopharyngeal ... Iron-deficiency Anemia | Iron Isomaltosi... Polysaccharide ... Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Intravenous Iron: Measuring Response in Anemic Surgical Patients | NCT02057471 | Colorectal Neop... Anemia | Intravenous fer... | 18 Years - | Nottingham University Hospitals NHS Trust | |
| RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia | NCT00495378 | Chemotherapy Cancer Anemia | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India | NCT05891249 | Anemia | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | NCT03933813 | Epithelial Ovar... Anemia Iron Deficiency... | Iron Sucrose | 18 Years - | University of Wisconsin, Madison | |
| A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies | NCT02564094 | Anemia | Epoetin beta | 18 Years - | Hoffmann-La Roche | |
| Survey on QUality of Life In myeloDisplasia (SQUID) | NCT00967564 | Myelodysplastic... | epidemiologic s... | 18 Years - | Janssen-Cilag S.p.A. | |
| Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status | NCT02835937 | Red Blood Cell ... Anemia Hematology Oncology Ambulatory Care | No-Transfuse | 18 Years - | Mayo Clinic | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy | NCT00120679 | Non-Small Cell ... Anemia | darbepoetin alf... recombinant hum... | 18 Years - | Amgen | |
| Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients | NCT01817699 | Kidney Transpla... Anemia Vitamin D Defic... Renal Insuffici... | High Hb target cholecalciferol | 20 Years - 79 Years | CANDLE-KIT Trial Study Group | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy | NCT01101399 | Iron-Deficiency... | Ferric carboxym... | 18 Years - | Vifor Pharma | |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy | NCT00216541 | Anemia Neoplasms | epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02048813 | Anemia Chronic Lymphoc... Small Lymphocyt... | Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes | NCT04701229 | Myelodysplastic... Myelodysplastic... Myelodysplastic... | somatic cytogen... | 18 Years - | University Hospital, Brest | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | NCT00145652 | Anemia Multiple Myelom... Non Hodgkin Lym... Chronic Lymphoc... | Neo-Recormon an... | 18 Months - | Sundsvall Hospital | |
| Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) | NCT00931606 | Chemotherapy In... | Sotatercept Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | NCT01284348 | Anemia Carcinoma, Non-... Carcinoma, Smal... Bladder Cancer Cancer of Head ... Uterine Cervica... | Sotatercept 15 ... Sotatercept 30 ... | 18 Years - | Merck Sharp & Dohme LLC | |
| Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer | NCT00258440 | Anemia Fatigue Unspecified Adu... | Weekly procrit ... Interval Dosing | 18 Years - | OHSU Knight Cancer Institute | |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00735930 | Anemia Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... Thrombocytopeni... | Alvocidib Hydro... Lenalidomide Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | NCT00017004 | Anemia Cervical Adenoc... Cervical Adenos... Cervical Squamo... Drug Toxicity Radiation Toxic... Stage IIB Cervi... Stage III Cervi... Stage IVA Cervi... | External Beam R... Cisplatin Internal Radiat... Epoetin Alfa | - | GOG Foundation | |
| Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia | NCT00004215 | Anemia Leukemia Neutropenia Thrombocytopeni... | filgrastim leridistim cytarabine daunorubicin hy... | 55 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants | NCT06045689 | Myelodysplastic... | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. | NCT00350090 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy | NCT02628860 | Pancreatic Canc... Anemia | Ferinject (Ferr... | 19 Years - | National Cancer Center, Korea | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | NCT05490446 | Myelodysplastic... | AG-946 Placebo | 18 Years - | Agios Pharmaceuticals, Inc. | |
| A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer | NCT00246597 | Anemia Breast Neoplasm... Hemoglobins Quality of Life Chemotherapy, A... | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy | NCT00083434 | Anemia Cancer | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02805868 | Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni... | Bone Marrow Asp... Laboratory Biom... Siltuximab | 18 Years - | Northwestern University | |
| One Versus Two Unit Transfusions in Oncology Patients - The OTTOP Trial: A Randomized Open-label Pragmatic Controlled Trial | NCT04544540 | Anemia Oncology | Units of transf... | 18 Years - | Ottawa Hospital Research Institute | |
| Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation | NCT03010579 | Anemia Lymphoma Hematopoietic S... | erythropoietin iron supplement... | 18 Years - 65 Years | Peking University | |
| A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy. | NCT00629876 | Anemia | Peginesatide | 18 Years - 80 Years | Takeda | |
| A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix | NCT00921635 | Cervical Cancer Anemia | Blood transfusi... Blood transfusi... | 18 Years - | Tri-Service General Hospital | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02048813 | Anemia Chronic Lymphoc... Small Lymphocyt... | Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | NCT00858364 | Non-Small Cell ... Anemia Cancer Lung Cancer | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors | NCT00772083 | Anemia Colorectal Canc... | Educational bro... Standard pamphl... | 18 Years - | Medical College of Wisconsin | |
| Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY) | NCT01725789 | Anemia | Ferinject® normal saline | 20 Years - | National Cancer Center, Korea | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) | NCT00931606 | Chemotherapy In... | Sotatercept Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | NCT00017004 | Anemia Cervical Adenoc... Cervical Adenos... Cervical Squamo... Drug Toxicity Radiation Toxic... Stage IIB Cervi... Stage III Cervi... Stage IVA Cervi... | External Beam R... Cisplatin Internal Radiat... Epoetin Alfa | - | GOG Foundation | |
| Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy | NCT00111137 | Cancer Non-Myeloid Mal... | rHuEPO Darbepoetin alf... | 18 Years - | Amgen | |
| A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy | NCT02624141 | Anemia | Epoetin Beta | 18 Years - | Hoffmann-La Roche | |
| Epoetin Beta in Treating Anemia in Patients With Cervical Cancer | NCT00046969 | Anemia Cervical Cancer | epoetin beta cisplatin brachytherapy radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy | NCT00270127 | Anemia Cancer Neoplasm | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | NCT05469737 | Myelodysplastic... | Oral Azacitidin... Placebo for Ora... | 18 Years - | Bristol-Myers Squibb | |
| PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy | NCT00388336 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00072059 | Anemia Lung Cancer | methoxy polyeth... | 18 Years - | National Cancer Institute (NCI) | |
| Cardiorespiratory Diagnostic Study | NCT04939558 | COPD Asthma Lung Cancer Anemia Congestive Card... Bronchiectasis Interstitial Lu... Long COVID Upper Respirato... Healthy | N-Tidal C hands... | 18 Years - | TidalSense | |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma | NCT04582539 | Myelodysplastic... Multiple Myelom... Anemia | INCB000928 | 18 Years - | Incyte Corporation | |
| Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer | NCT00091858 | Anemia Cancer | Darbepoetin Alf... Placebo | 18 Years - | Amgen | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT00446602 | Myelodysplastic... Anemia | Epoetin alfa | 18 Years - 99 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy | NCT00216541 | Anemia Neoplasms | epoetin alfa | 18 Years - | Janssen-Cilag B.V. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
